---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053341"
form_type: "8-K"
ticker: "GRAL"
cik: "0001699031"
company_name: "GRAIL, Inc."
filed_at: "2026-08-05T20:08:32+00:00"
generated_at: "2026-08-05T20:11:25.672177+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GRAIL Q2 2026 revenue up 26% to $44.7M; Galleri volume up 35% YoY; net loss $110.2M

## Summary
- Total revenue $44.7M (+26% YoY); Galleri test revenue $42.6M (+24% YoY); test volume >61,000 (+35% YoY).
- Net loss $110.2M, improved $3.7M (3%) YoY; gross loss $12.6M, improved 29%.
- Non-GAAP adjusted gross profit $21.6M (+34% YoY); adjusted EBITDA -$90.3M.
- Completed $110M equity financing with Samsung; PMA submitted, FDA advisory committee expected in fall.
- Presented NHS-Galleri and PATHFINDER 2 results at ASCO 2026, showing consistent performance.

## SEC filing metadata
- accession: 0001628280-26-053341
- form_type: 8-K
- ticker: GRAL
- cik: 0001699031
- company_name: GRAIL, Inc.
- filed_at: 2026-08-05T20:08:32+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699031/000162828026053341/0001628280-26-053341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699031/000162828026053341/gral-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053341
- JSON: https://secwatch.observer/filing/0001628280-26-053341.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.